Evidence map›Paper›PMID 34952646›Full record

ReviewCell & bioscience2021

The eukaryotic initiation factor 5A (eIF5A1), the molecule, mechanisms and recent insights into the pathophysiological roles.

Michel Tauc, Marc Cougnon, Romain Carcy, Nicolas Melis, Thierry Hauet, Luc Pellerin, Nicolas Blondeau, Didier F Pisani

Open access · goldAbstract readReview
In one paragraph

Review in Cell & bioscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. eIF5A coordinates the transcription and translation of its target genes.Cellular and molecular life sciences : CMLS · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. The Effects of Lipid Extracts from MicroalgaeAntioxidants (Basel, Switzerland) · 2025
    Article
  11. Article
  12. AI-Driven Prediction of Cardio-Oncology Biomarkers Through Protein Corona Analysis.Chemical engineering journal (Lausanne, Switzerland : 1996) · 2025
    Article
  13. Genomic Insight into Primary Adaptation ofAntibiotics (Basel, Switzerland) · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. The role of polyamine metabolism in cellular function and physiology.American journal of physiology. Cell physiology · 2024
    Review
  18. Review
  19. Structural Insights into the Mechanisms Underlying Polyaminopathies.International journal of molecular sciences · 2024
    Review
  20. What Is All of the Hype About? Hypusine Signaling as a Driver of Pulmonary Hypertension.American journal of respiratory and critical care medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Michel TaucLP2M, CNRS, Université Côte d'Azur, Nice, France. michel.tauc@univ-cotedazur.fr.ORCID http://orcid.org/0000-0002-8383-9818
Marc CougnonLP2M, CNRS, Université Côte d'Azur, Nice, France.
Romain CarcyService de Réanimation Polyvalente et Service de Réanimation des Urgences Vitales, CHU Nice, Hôpital Pasteur 2, Nice, France.
Nicolas MelisLaboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA.
Thierry HauetINSERM, IRTOMIT, CHU de Poitiers, Université de Poitiers, La Milétrie, Poitiers, France.
Luc PellerinINSERM, IRTOMIT, CHU de Poitiers, Université de Poitiers, La Milétrie, Poitiers, France.
Nicolas BlondeauLaboratories of Excellence Ion Channel Science and Therapeutics, Nice, France.
Didier F PisaniLP2M, CNRS, Université Côte d'Azur, Nice, France.
Centre National de la Recherche Scientifique · FRInserm · FRHôpital Pasteur · FRNational Cancer Institute · US

Funding

agence nationale de la recherche KIRIAgence Nationale de la Recherche hypusin_oxiefrm DPM 20121125559
6 · The paper itself

Abstract

Since the demonstration of its involvement in cell proliferation, the eukaryotic initiation factor 5A (eIF5A) has been studied principally in relation to the development and progression of cancers in which the isoform A2 is mainly expressed. However, an increasing number of studies report that the isoform A1, which is ubiquitously expressed in normal cells, exhibits novel molecular features that reveal its new relationships between cellular functions and organ homeostasis. At a first glance, eIF5A can be regarded, among other things, as a factor implicated in the initiation of translation. Nevertheless, at least three specificities: (1) its extreme conservation between species, including plants, throughout evolution, (2) its very special and unique post-translational modification through the activating-hypusination process, and finally (3) its close relationship with the polyamine pathway, suggest that the role of eIF5A in living beings remains to be uncovered. In fact, and beyond its involvement in facilitating the translation of proteins containing polyproline residues, eIF5A is implicated in various physiological processes including ischemic tolerance, metabolic adaptation, aging, development, and immune cell differentiation. These newly discovered physiological properties open up huge opportunities in the clinic for pathologies such as, for example, the ones in which the oxygen supply is disrupted. In this latter case, organ transplantation, myocardial infarction or stroke are concerned, and the current literature defines eIF5A as a new drug target with a high level of potential benefit for patients with these diseases or injuries. Moreover, the recent use of genomic and transcriptomic association along with metadata studies also revealed the implication of eIF5A in genetic diseases. Thus, this review provides an overview of eIF5A from its molecular mechanism of action to its physiological roles and the clinical possibilities that have been recently reported in the literature.

Identifiers

PMID34952646
PMCPMC8705083
OpenAlexW4200194241

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.